Vimarsana
Biggest News Aggregation in the World

Page 13 - Multiple Sclerosis Centers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Centers Today - Breaking & Trending Today

Safety, Efficacy of Dimethyl Fumarate for Multiple Sclerosis in Minority Groups - Vimarsana News

Safety, Efficacy of Dimethyl Fumarate for Multiple Sclerosis in Minority Groups

Black/African American and Hispanic/Latino patients with multiple sclerosis saw a treatment benefit with dimethyl fumarate.

Inebilizumab Beneficial Across Genotypes in NMOSD - Vimarsana News

Inebilizumab Beneficial Across Genotypes in NMOSD

Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.

Cognitive Processing Speed Changes in Relapsing MS With Ublituximab Treatment - Vimarsana News

Cognitive Processing Speed Changes in Relapsing MS With Ublituximab Treatment

Among patients with highly active relapsing MS, use of ublituximab led to improvement in cognitive processing speed at 96 weeks compared with teriflunomide.

Nabiximols Treatment Effect on Spasticity in Patients With MS - Vimarsana News

Nabiximols Treatment Effect on Spasticity in Patients With MS

Nabiximols has a significant treatment effect on spasticity in patients with MS who are either being treated with or without antispasticity medications.

Non-White MS Patients Rarely Included in Trials - Vimarsana News

Non-White MS Patients Rarely Included in Trials

Over 25 years of clinical research, phase 3 trials of approved disease-modifying therapies for multiple sclerosis were overwhelmingly made up of White participants, new research shows.